<?xml version='1.0' encoding='utf-8'?>
<document id="22534255"><sentence text="Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers."><entity charOffset="11-23" id="DDI-PubMed.22534255.s1.e0" text="ketoconazole" /><entity charOffset="28-38" id="DDI-PubMed.22534255.s1.e1" text="rifampicin" /><entity charOffset="66-77" id="DDI-PubMed.22534255.s1.e2" text="gemigliptin" /><pair ddi="false" e1="DDI-PubMed.22534255.s1.e0" e2="DDI-PubMed.22534255.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22534255.s1.e0" e2="DDI-PubMed.22534255.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22534255.s1.e0" e2="DDI-PubMed.22534255.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22534255.s1.e1" e2="DDI-PubMed.22534255.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22534255.s1.e1" e2="DDI-PubMed.22534255.s1.e2" /></sentence><sentence text="Gemigliptin (LC15-0444) is a newly developed selective and competitive inhibitor of dipeptidyl peptidase (DPP)-4 and has potential for the treatment of type 2 diabetes mellitus"><entity charOffset="0-11" id="DDI-PubMed.22534255.s2.e0" text="Gemigliptin" /><entity charOffset="13-22" id="DDI-PubMed.22534255.s2.e1" text="LC15-0444" /><pair ddi="false" e1="DDI-PubMed.22534255.s2.e0" e2="DDI-PubMed.22534255.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22534255.s2.e0" e2="DDI-PubMed.22534255.s2.e1" /></sentence><sentence text=" Gemigliptin is metabolized by the cytochrome P450 (CYP) 3A4 isozyme to yield the active major metabolite LC15-0636"><entity charOffset="1-12" id="DDI-PubMed.22534255.s3.e0" text="Gemigliptin" /></sentence><sentence text="" /><sentence text="The effects of multiple oral doses of ketoconazole (a potent CYP3A4 inhibitor) and multiple oral doses of rifampicin (a potent CYP3A4 inducer) on the pharmacokinetic properties of a single oral dose of gemigliptin were evaluated in fasting healthy male Korean volunteers"><entity charOffset="38-50" id="DDI-PubMed.22534255.s5.e0" text="ketoconazole" /><entity charOffset="106-116" id="DDI-PubMed.22534255.s5.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.22534255.s5.e0" e2="DDI-PubMed.22534255.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22534255.s5.e0" e2="DDI-PubMed.22534255.s5.e1" /></sentence><sentence text="" /><sentence text="In this open-label, 2-part, 3-treatment, 1-sequence, 2-period crossover drug-drug interaction study, 1 group of subjects received a single 50-mg oral dose of gemigliptin on 2 separate occasions-once as monotherapy and again after pretreatment with 400 mg of oral ketoconazole once daily for 7 days"><entity charOffset="158-169" id="DDI-PubMed.22534255.s7.e0" text="gemigliptin" /><entity charOffset="263-275" id="DDI-PubMed.22534255.s7.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.22534255.s7.e0" e2="DDI-PubMed.22534255.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22534255.s7.e0" e2="DDI-PubMed.22534255.s7.e1" /></sentence><sentence text=" The other group of subjects received a single 50-mg oral dose of gemigliptin on 2 separate occasions-once without pretreatment and again after pretreatment with 600 mg of oral rifampicin once daily for 10 days"><entity charOffset="66-77" id="DDI-PubMed.22534255.s8.e0" text="gemigliptin" /><entity charOffset="177-187" id="DDI-PubMed.22534255.s8.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.22534255.s8.e0" e2="DDI-PubMed.22534255.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22534255.s8.e0" e2="DDI-PubMed.22534255.s8.e1" /></sentence><sentence text=" Blood samples were obtained at 0 (predose), 0" /><sentence text="5, 1, 1" /><sentence text="5, 2, 3, 4, 5, 6, 8, 12, 24, 48, and 72 hours after gemigliptin dosing" /><sentence text=" Plasma concentrations were determined using LC-MS/MS" /><sentence text=" Pharmacokinetic parameters were estimated via noncompartmental methods" /><sentence text=" Tolerability was assessed using measurements of vital signs, clinical chemistry tests, and interviews" /><sentence text="" /><sentence text="Twenty-four subjects were enrolled (12 per group)" /><sentence text=" Concurrent administration of ketoconazole was associated with increased total gemigliptin plasma exposure (AUC(0-∞); 2"><entity charOffset="30-42" id="DDI-PubMed.22534255.s17.e0" text="ketoconazole" /></sentence><sentence text="36-fold [90% CI, 2" /><sentence text="19-2" /><sentence text="54]) and decreased metabolism of gemigliptin until negligible concentrations of LC15-0636 were detected"><entity charOffset="33-44" id="DDI-PubMed.22534255.s20.e0" text="gemigliptin" /></sentence><sentence text=" Pretreatment with rifampicin was associated with decreased AUC(0-∞) of gemigliptin (by 80% [90% CI, 78%-82%]) and a 2"><entity charOffset="19-29" id="DDI-PubMed.22534255.s21.e0" text="rifampicin" /><entity charOffset="72-83" id="DDI-PubMed.22534255.s21.e1" text="gemigliptin" /><pair ddi="false" e1="DDI-PubMed.22534255.s21.e0" e2="DDI-PubMed.22534255.s21.e0" /><pair ddi="false" e1="DDI-PubMed.22534255.s21.e0" e2="DDI-PubMed.22534255.s21.e1" /></sentence><sentence text="9-fold increase (mean [SD], 0" /><sentence text="18 [0" /><sentence text="08] to 0" /><sentence text="52 [0" /><sentence text="10]) in the metabolic ratio of gemigliptin to LC15-0636"><entity charOffset="31-42" id="DDI-PubMed.22534255.s26.e0" text="gemigliptin" /></sentence><sentence text=" The treatments were well-tolerated, with no severe adverse events reported" /><sentence text=" Six of the 24 subjects (25%) experienced AEs during the first period of gemigliptin monotherapy administration" /><sentence text=" Six of 12 subjects (50%) each experienced AEs during concurrent administration with ketoconazole and rifampicin"><entity charOffset="85-97" id="DDI-PubMed.22534255.s29.e0" text="ketoconazole" /><entity charOffset="102-112" id="DDI-PubMed.22534255.s29.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.22534255.s29.e0" e2="DDI-PubMed.22534255.s29.e0" /><pair ddi="false" e1="DDI-PubMed.22534255.s29.e0" e2="DDI-PubMed.22534255.s29.e1" /></sentence><sentence text="" /><sentence text="In this select group of healthy male Korean volunteers, concurrent administration of gemigliptin with ketoconazole or rifampicin was associated with significantly increased or decreased systemic exposure to gemigliptin, respectively"><entity charOffset="85-96" id="DDI-PubMed.22534255.s31.e0" text="gemigliptin" /><entity charOffset="102-114" id="DDI-PubMed.22534255.s31.e1" text="ketoconazole" /><entity charOffset="118-128" id="DDI-PubMed.22534255.s31.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.22534255.s31.e0" e2="DDI-PubMed.22534255.s31.e0" /><pair ddi="false" e1="DDI-PubMed.22534255.s31.e0" e2="DDI-PubMed.22534255.s31.e1" /><pair ddi="false" e1="DDI-PubMed.22534255.s31.e0" e2="DDI-PubMed.22534255.s31.e2" /><pair ddi="false" e1="DDI-PubMed.22534255.s31.e1" e2="DDI-PubMed.22534255.s31.e1" /><pair ddi="false" e1="DDI-PubMed.22534255.s31.e1" e2="DDI-PubMed.22534255.s31.e2" /></sentence><sentence text=" These findings suggest that gemigliptin may require a dose adjustment when concurrently administered with drugs that alter CYP3A4 activity"><entity charOffset="29-40" id="DDI-PubMed.22534255.s32.e0" text="gemigliptin" /></sentence><sentence text=" Concurrent administration of gemigliptin with ketoconazole or rifampicin was well tolerated"><entity charOffset="30-41" id="DDI-PubMed.22534255.s33.e0" text="gemigliptin" /><entity charOffset="47-59" id="DDI-PubMed.22534255.s33.e1" text="ketoconazole" /><entity charOffset="63-73" id="DDI-PubMed.22534255.s33.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.22534255.s33.e0" e2="DDI-PubMed.22534255.s33.e0" /><pair ddi="false" e1="DDI-PubMed.22534255.s33.e0" e2="DDI-PubMed.22534255.s33.e1" /><pair ddi="false" e1="DDI-PubMed.22534255.s33.e0" e2="DDI-PubMed.22534255.s33.e2" /><pair ddi="false" e1="DDI-PubMed.22534255.s33.e1" e2="DDI-PubMed.22534255.s33.e1" /><pair ddi="false" e1="DDI-PubMed.22534255.s33.e1" e2="DDI-PubMed.22534255.s33.e2" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT01426906" /><sentence text="" /></document>